Tobira Therapeutics Inc. (NASDAQ:TBRA) major shareholder Pentwater Capital Management L acquired 50,000 shares of the stock in a transaction on Monday, September 26th. The stock was bought at an average cost of $39.00 per share, for a total transaction of $1,950,000.00. The purchase was disclosed in a filing with the SEC, which is available at this hyperlink. Major shareholders that own 10% or more of a company’s stock are required to disclose their transactions with the SEC.
Pentwater Capital Management L also recently made the following trade(s):
- On Friday, September 23rd, Pentwater Capital Management L acquired 100,000 shares of Tobira Therapeutics stock. The stock was bought at an average cost of $39.19 per share, for a total transaction of $3,919,000.00.
- On Thursday, September 22nd, Pentwater Capital Management L acquired 1,624,200 shares of Tobira Therapeutics stock. The stock was bought at an average cost of $39.04 per share, for a total transaction of $63,408,768.00.
Shares of Tobira Therapeutics Inc. (NASDAQ:TBRA) opened at 39.49 on Friday. Tobira Therapeutics Inc. has a 52-week low of $3.76 and a 52-week high of $41.39. The stock has a 50 day moving average of $12.68 and a 200 day moving average of $9.83. The company’s market cap is $743.24 million.
Tobira Therapeutics (NASDAQ:TBRA) last released its earnings results on Tuesday, August 9th. The biopharmaceutical company reported ($0.71) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.63) by $0.08. The firm had revenue of $1.06 million for the quarter. On average, equities research analysts expect that Tobira Therapeutics Inc. will post ($2.65) EPS for the current year.
Several brokerages have commented on TBRA. Zacks Investment Research lowered shares of Tobira Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday, July 28th. Cantor Fitzgerald lowered shares of Tobira Therapeutics to a “buy” rating and set a $19.00 price objective on the stock. in a research report on Monday, July 25th. HC Wainwright reaffirmed a “buy” rating on shares of Tobira Therapeutics in a research report on Tuesday, June 28th. Mizuho reaffirmed a “buy” rating and issued a $305.00 price objective on shares of Tobira Therapeutics in a research report on Thursday, September 22nd. Finally, Cowen and Company reaffirmed a “buy” rating and issued a $11.00 price objective on shares of Tobira Therapeutics in a research report on Wednesday, August 10th. One analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average price target of $68.63.
Hedge funds have recently added to or reduced their stakes in the company. Franklin Resources Inc. acquired a new stake in Tobira Therapeutics during the first quarter worth $4,797,000. BB Biotech AG acquired a new stake in Tobira Therapeutics during the second quarter worth $5,878,000. AXA acquired a new stake in Tobira Therapeutics during the second quarter worth $3,472,000. BlackRock Fund Advisors increased its stake in Tobira Therapeutics by 256.8% in the second quarter. BlackRock Fund Advisors now owns 227,775 shares of the biopharmaceutical company’s stock worth $2,861,000 after buying an additional 163,943 shares in the last quarter. Finally, State Street Corp increased its stake in Tobira Therapeutics by 155.5% in the second quarter. State Street Corp now owns 109,527 shares of the biopharmaceutical company’s stock worth $1,377,000 after buying an additional 66,652 shares in the last quarter. 62.02% of the stock is currently owned by hedge funds and other institutional investors.
About Tobira Therapeutics
Tobira Therapeutics, Inc, formerly Regado Biosciences, Inc, is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies to treat liver disease, inflammation, fibrosis and human immunodeficiency virus (HIV). The Company’s lead product candidate, cenicriviroc (CVC), is an immunomodulator and dual inhibitor of C-C Chemokine Receptor 2 (CCR2) and C-C Chemokine Receptor 5 (CCR5) being evaluated for the treatment of non-alcoholic steatohepatitis (NASH), primary sclerosing cholangitis (PSC), and as an adjunctive therapy to standard of care in HIV.
Receive News & Ratings for Tobira Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tobira Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.